Last year, TherapeuticsMD Inc generated 68.56M USD for its biggest-performing segment, Mayne Pharma. The United States made the largest contribution, accounting for 86.95M USD last year. For the latest quarter, TherapeuticsMD Inc reported the revenue of 68.56M USD for the period ending 2022-12-31, which came from the top-performing segment, Mayne Pharma. United States contributed the highest revenue, at 489.00K USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Mayne Pharma

Theramex

IMVEXXY

ANNOVERA

Prescription vitamins

BIJUVA

License revenue

OTC Products

FY2022

FY2021

FY2020

FY2019

FY2018

Mayne Pharma

68.56M(98.00%)

--(--)

Theramex

1.40M(2.00%)

2.57M(100.00%)

--(--)

IMVEXXY

--(--)

27.14M(41.84%)

16.25M(32.74%)

1.06M(6.57%)

ANNOVERA

--(--)

19.61M(30.23%)

6.17M(12.42%)

--(--)

Prescription vitamins

--(--)

9.77M(15.06%)

9.89M(19.91%)

15.04M(93.43%)

BIJUVA

--(--)

6.35M(9.79%)

1.84M(3.70%)

--(--)

License revenue

--(--)

2.00M(3.08%)

15.51M(31.23%)

--(--)

OTC Products

--(--)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

FY2021

United States

86.95M(100.00%)